|
1
|
Dumic J, Dabelic S and Flögel M:
Galectin-3: An open-ended story. Biochim Biophys Acta.
1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barondes SH, Castronovo V, Cooper DN,
Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes
C, Kasai K, et al: Galectins: A family of animal
β-galactoside-binding lectins. Cell. 76:597–598. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ochieng J, Fridman R, Nangia-Makker P,
Kleiner DE, Liotta LA, Stetler-Stevenson WG and Raz A: Galectin-3
is a novel substrate for human matrix metalloproteinases-2 and -9.
Biochemistry. 33:14109–14114. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gong HC, Honjo Y, Nangia-Makker P, Hogan
V, Mazurak N, Bresalier RS and Raz A: The NH2 terminus of
galectin-3 governs cellular compartmentalization and functions in
cancer cells. Cancer Res. 59:6239–6245. 1999.
|
|
5
|
Zhang HY, Jin L, Stilling GA, Ruebel KH,
Coonse K, Tanizaki Y, Raz A and Lloyd RV: RUNX1 and RUNX2
upregulate Galectin-3 expression in human pituitary tumors.
Endocrine. 35:101–111. 2009. View Article : Google Scholar
|
|
6
|
Sakaki M, Fukumori T, Fukawa T, Elsamman
E, Shiirevnyamba A, Nakatsuji H and Kanayama HO: Clinical
significance of Galectin-3 in clear cell renal cell carcinoma. J
Med Invest. 57:152–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jia W, Kidoya H, Yamakawa D, Naito H and
Takakura N: Galectin-3 accelerates M2 macrophage infiltration and
angio-genesis in tumors. Am J Pathol. 182:1821–1831. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu SW, Yu L, Zhou L, Cheng ZN and Tao YS:
Expression of Gal-3 and CD82/KAI1 proteins in non-small cell lung
cancer and their clinical significance. Chinese Journal of
Oncology. 35:124–128. 2013.In Chinese.
|
|
9
|
Ochieng J, Furtak V and Lukyanov P:
Extracellular functions of galectin-3. Glycoconj J. 19:527–535.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu F, Finley RL Jr, Raz A and Kim HR:
Galectin-3 translocates to the perinuclear membranes and inhibits
cytochrome c release from the mitochondria. A role for synexin in
galectin-3 translocation. J Biol Chem. 277:15819–15827. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takenaka Y, Fukumori T, Yoshii T, Oka N,
Inohara H, Kim HR, Bresalier RS and Raz A: Nuclear export of
phosphorylated galectin-3 regulates its antiapoptotic activity in
response to chemotherapeutic drugs. Mol Cell Biol. 24:4395–4406.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patterson RJ, Wang W and Wang JL:
Understanding the biochemical activities of galectin-1 and
galectin-3 in the nucleus. Glycoconj J. 19:499–506. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimura T, Takenaka Y, Tsutsumi S, Hogan
V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of
beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Braeuer RR, Shoshan E, Kamiya T and
Bar-Eli M: The sweet and bitter sides of galectins in melanoma
progression. Pigment Cell Melanoma Res. 25:592–601. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lotan R, Ito H, Yasui W, Yokozaki H, Lotan
D and Tahara E: Expression of a 31-kDa lactose-binding lectin in
normal human gastric mucosa and in primary and metastatic gastric
carcinomas. Int J Cancer. 56:474–480. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inohara H, Honjo Y, Yoshii T, Akahani S,
Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A and Kubo T:
Expression of galectin-3 in fine-needle aspirates as a diagnostic
marker differentiating benign from malignant thyroid neoplasms.
Cancer. 85:2475–2484. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rice TW, Rusch VW, Apperson-Hansen C,
Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE,
et al: Worldwide esophageal cancer collaboration. Dis Esophagus.
22:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang N, Song X, Xie J, Xu D, Liu F, Yu X,
Tian Y, Liu Z, Qiao L and Zhang J: Effect of galectin-3 on the
behavior of Eca-109 human esophageal cancer cells. Mol Med Rep.
11:896–902. 2015.
|
|
20
|
Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma
M and Liu JF: The tumor-suppressive function of miR-1 by targeting
LASP1 and TAGLN2 in esophageal squamous cell carcinoma. J
Gastroenterol Hepatol. Epub ahead of print. 2015. View Article : Google Scholar
|
|
21
|
Li S, Qin X, Li Y, Zhang X, Niu R, Zhang
H, Cui A, An W and Wang X: MiR-133a suppresses the migration and
invasion of esophageal cancer cells by targeting the EMT regulator
SOX4. Am J Transl Res. 7:1390–1403. 2015.PubMed/NCBI
|
|
22
|
Zhou W, Yue H, Li C, Chen H and Yuan Y:
Protein arginine methyltransferase 1 promoted the growth and
migration of cancer cells in esophageal squamous cell carcinoma.
Tumour Biol. 2015.
|
|
23
|
Pei Y, Wang P, Liu H, He F and Ming L:
FOXQ1 promotes esophageal cancer proliferation and metastasis by
negatively modulating CDH1. Biomed Pharmacother. 74:89–94. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Zhu SC, Li SG, Zhao Y, Xu JR and
Song CY: TKTL1 promotes cell proliferation and metastasis in
esophageal squamous cell carcinoma. Biomed Pharmacother. 74:71–76.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hood JD and Cheresh DA: Role of integrins
in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002.
View Article : Google Scholar
|
|
27
|
Liu FT and Rabinovich GA: Galectins as
modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kobayashi T, Shimura T, Yajima T, Kubo N,
Araki K, Tsutsumi S, Suzuki H, Kuwano H and Raz A: Transient gene
silencing of galectin-3 suppresses pancreatic cancer cell migration
and invasion through degradation of β-catenin. Int J Cancer.
129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Honjo Y, Nangia-Makker P, Inohara H and
Raz A: Down-regulation of Galectin-3 suppresses tumorigenicity of
human breast carcinoma cells. Clin Cancer Res. 7:661–668.
2001.PubMed/NCBI
|
|
30
|
Bresalier RS, Mazurek N, Sternberg LR,
Byrd JC, Yunker CK, Nangia-Makker P and Raz A: Metastasis of human
colon cancer is altered by modifying expression of the
beta-galactoside-binding protein galectin-3. Gastroenterology.
115:287–296. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hittelet A, Camby I, Nagy N, Legendre H,
Bronckart Y, Decaestecker C, Kaltner H, Nifant'ev NE, Bovin NV,
Pector JC, et al: Binding sites for lewis antigens are expressed by
human colon cancer cells and negatively affect their migration. Lab
Invest. 83:777–787. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Debray C, Vereecken P, Belot N, Teillard
P, Brion JP, Pandolfo M and Pochet R: Multifaceted role of
galectin-3 on human glioblastoma cell motility. Biochem Biophys Res
Commun. 325:1393–1398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Glinsky VV, Glinsky GV, Glinskii OV,
Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ and Quinn
TP: Intravascular metastatic cancer cell homotypic aggregation at
the sites of primary attachment to the endothelium. Cancer Res.
63:3805–3811. 2003.PubMed/NCBI
|
|
34
|
O'Driscoll L, Linehan R, Liang YH, Joyce
H, Oglesby I and Clynes M: Galectin-3 expression alters adhesion,
motility and invasion in a lung cell line (DLKP), in vitro.
Anticancer Res. 22:3117–3125. 2002.
|
|
35
|
Junking M, Wongkham C, Sripa B,
Sawanyawisuth K, Araki N and Wongkham S: Decreased expression of
galectin-3 is associated with metastatic potential of liver
fluke-associated cholangiocarcinoma. Eur J Cancer. 44:619–626.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Endo K, Kohnoe S, Tsujita E, Watanabe A,
Nakashima H, Baba H and Maehara Y: Galectin-3 expression is a
potent prognostic marker in colorectal cancer. Anticancer Res.
25:3117–3121. 2005.PubMed/NCBI
|
|
37
|
Shi Y, He B, Kuchenbecker KM, You L, Xu Z,
Mikami I, Yagui-Beltran A, Clement G, Lin YC, Okamoto J, et al:
Inhibition of Wnt-2 and galectin-3 synergistically destabilizes
beta-catenin and induces apoptosis in human colorectal cancer
cells. Int J Cancer. 121:1175–1181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zaia Povegliano L, Oshima CT, de Oliveira
Lima F, Andrade Scherholz PL and Manoukian Forones N:
Immunoexpression of galectin-3 in colorectal cancer and its
relationship with survival. J Gastrointest Cancer. 42:217–221.
2011. View Article : Google Scholar
|
|
39
|
Lotz MM, Andrews CW Jr, Korzelius CA, Lee
EC, Steele GD Jr, Clarke A and Mercurio AM: Decreased expression of
Mac-2 (carbohydrate binding protein 35) and loss of its nuclear
localization are associated with the neoplastic progression of
colon carcinoma. Proc Natl Acad Sci USA. 90:3466–3470. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu L, Sakai T, Sano N and Fukui K:
Nucling mediates apoptosis by inhibiting expression of galectin-3
through interference with nuclear factor kappaB signaling. Biochem
J. 380:31–41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dumic J, Lauc G and Flögel M: Expression
of galectin-3 in cells exposed to stress-roles of jun and
NF-kappaB. Cell Physiol Biochem. 10:149–158. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baichwal VR and Baeuerle PA: Activate
NF-kappaB or die? Curr Biol. 7:R94–R96. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baeuerle PA and Henkel T: Function and
activation of NF-kappaB in the immune system. Annu Rev Immunol.
12:141–179. 1994. View Article : Google Scholar
|
|
44
|
Lin CI, Whang EE, Abramson MA, Donner DB,
Bertagnolli MM, Moore FD Jr and Ruan DT: Galectin-3 regulates
apoptosis and doxorubicin chemoresistance in papillary thyroid
cancer cells. Biochem Biophys Res Commun. 379:626–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oka N, Nakahara S, Takenaka Y, Fukumori T,
Hogan V, Kanayama HO, Yanagawa T and Raz A: Galectin-3 inhibits
tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis by activating Akt in human bladder carcinoma cells.
Cancer Res. 65:7546–7553. 2005.PubMed/NCBI
|
|
46
|
Choi JH, Chun KH, Raz A and Lotan R:
Inhibition of N-(4-hydroxyphenyl) retinamide-induced apoptosis in
breast cancer cells by galectin-3. Cancer Biol Ther. 3:447–452.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tepsiri N, Chaturat L, Sripa B, Namwat W,
Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity
and drug resistance profiles of human intrahepatic
cholangiocar-cinoma cell lines. World J Gastroenterol.
11:2748–2753. 2005. View Article : Google Scholar : PubMed/NCBI
|
